The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Venous thromboembolism (VTE) Therapeutics-Global Market Insights and Sales Trends 2024
Synopsis
Venous thromboembolism (VTE), which is composed of deep vein thrombosis (DVT) and pulmonary embolism (PE), is a blood clot (thrombosis) of the circulatory system that leads to impeded blood flow, which can have serious consequences in the affected individual (Heit, 2015). In VTE, a DVT is a clot that occurs only in the veins; generally, they occur in the deep veins of the legs and pelvis, but may also occur in the veins of the upper body (AHA, 2017; Cohen et al., 2007; Heit, 2015). The clot may break off from its original location and travel throughout the circulatory system, and if the clot ends up in the lung, it is known as a PE
The global Venous thromboembolism (VTE) Therapeutics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Venous thromboembolism (VTE) Therapeutics in various end use industries. The expanding demands from the Hospital, Ambulatory Surgery Centers, Research Institutes and Others, are propelling Venous thromboembolism (VTE) Therapeutics market. Deep Vein Thrombosis(DVT), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Pulmonary Embolism(PE) segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Venous thromboembolism (VTE) Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Venous thromboembolism (VTE) Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Venous thromboembolism (VTE) Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Venous thromboembolism (VTE) Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Venous thromboembolism (VTE) Therapeutics covered in this report include Boehringer Ingelheim, Bayer, Janssen, Bristol-Myers Squibb, Pfizer, Daiichi-Sankyo, Portola Pharmaceuticals and Armetheon, etc.
The global Venous thromboembolism (VTE) Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Boehringer Ingelheim
Bayer
Janssen
Bristol-Myers Squibb
Pfizer
Daiichi-Sankyo
Portola Pharmaceuticals
Armetheon
Global Venous thromboembolism (VTE) Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Venous thromboembolism (VTE) Therapeutics market, Segment by Type:
Deep Vein Thrombosis(DVT)
Pulmonary Embolism(PE)
Others
Global Venous thromboembolism (VTE) Therapeutics market, by Application
Hospital
Ambulatory Surgery Centers
Research Institutes
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Venous thromboembolism (VTE) Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Venous thromboembolism (VTE), which is composed of deep vein thrombosis (DVT) and pulmonary embolism (PE), is a blood clot (thrombosis) of the circulatory system that leads to impeded blood flow, which can have serious consequences in the affected individual (Heit, 2015). In VTE, a DVT is a clot that occurs only in the veins; generally, they occur in the deep veins of the legs and pelvis, but may also occur in the veins of the upper body (AHA, 2017; Cohen et al., 2007; Heit, 2015). The clot may break off from its original location and travel throughout the circulatory system, and if the clot ends up in the lung, it is known as a PE
The global Venous thromboembolism (VTE) Therapeutics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Venous thromboembolism (VTE) Therapeutics in various end use industries. The expanding demands from the Hospital, Ambulatory Surgery Centers, Research Institutes and Others, are propelling Venous thromboembolism (VTE) Therapeutics market. Deep Vein Thrombosis(DVT), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Pulmonary Embolism(PE) segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Venous thromboembolism (VTE) Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Venous thromboembolism (VTE) Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Venous thromboembolism (VTE) Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Venous thromboembolism (VTE) Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Venous thromboembolism (VTE) Therapeutics covered in this report include Boehringer Ingelheim, Bayer, Janssen, Bristol-Myers Squibb, Pfizer, Daiichi-Sankyo, Portola Pharmaceuticals and Armetheon, etc.
The global Venous thromboembolism (VTE) Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Boehringer Ingelheim
Bayer
Janssen
Bristol-Myers Squibb
Pfizer
Daiichi-Sankyo
Portola Pharmaceuticals
Armetheon
Global Venous thromboembolism (VTE) Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Venous thromboembolism (VTE) Therapeutics market, Segment by Type:
Deep Vein Thrombosis(DVT)
Pulmonary Embolism(PE)
Others
Global Venous thromboembolism (VTE) Therapeutics market, by Application
Hospital
Ambulatory Surgery Centers
Research Institutes
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Venous thromboembolism (VTE) Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Venous thromboembolism (VTE) Therapeutics
1.1 Venous thromboembolism (VTE) Therapeutics Market Overview
1.1.1 Venous thromboembolism (VTE) Therapeutics Product Scope
1.1.2 Venous thromboembolism (VTE) Therapeutics Market Status and Outlook
1.2 Global Venous thromboembolism (VTE) Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Venous thromboembolism (VTE) Therapeutics Market Size by Region (2018-2029)
1.4 Global Venous thromboembolism (VTE) Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Venous thromboembolism (VTE) Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Venous thromboembolism (VTE) Therapeutics Market Size (2018-2029)
1.6.1 North America Venous thromboembolism (VTE) Therapeutics Market Size (2018-2029)
1.6.2 Europe Venous thromboembolism (VTE) Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Venous thromboembolism (VTE) Therapeutics Market Size (2018-2029)
1.6.4 Latin America Venous thromboembolism (VTE) Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Venous thromboembolism (VTE) Therapeutics Market Size (2018-2029)
2 Venous thromboembolism (VTE) Therapeutics Market by Type
2.1 Introduction
2.1.1 Deep Vein Thrombosis(DVT)
2.1.2 Pulmonary Embolism(PE)
2.1.3 Others
2.2 Global Venous thromboembolism (VTE) Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Venous thromboembolism (VTE) Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Venous thromboembolism (VTE) Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Venous thromboembolism (VTE) Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Venous thromboembolism (VTE) Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Venous thromboembolism (VTE) Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Venous thromboembolism (VTE) Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Venous thromboembolism (VTE) Therapeutics Revenue Breakdown by Type (2018-2029)
3 Venous thromboembolism (VTE) Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Hospital
3.1.2 Ambulatory Surgery Centers
3.1.3 Research Institutes
3.1.4 Others
3.2 Global Venous thromboembolism (VTE) Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Venous thromboembolism (VTE) Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global Venous thromboembolism (VTE) Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Venous thromboembolism (VTE) Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Venous thromboembolism (VTE) Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Venous thromboembolism (VTE) Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Venous thromboembolism (VTE) Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Venous thromboembolism (VTE) Therapeutics Revenue Breakdown by Application (2018-2029)
4 Venous thromboembolism (VTE) Therapeutics Competition Analysis by Players
4.1 Global Venous thromboembolism (VTE) Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Venous thromboembolism (VTE) Therapeutics as of 2022)
4.3 Date of Key Players Enter into Venous thromboembolism (VTE) Therapeutics Market
4.4 Global Top Players Venous thromboembolism (VTE) Therapeutics Headquarters and Area Served
4.5 Key Players Venous thromboembolism (VTE) Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Venous thromboembolism (VTE) Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Boehringer Ingelheim
5.1.1 Boehringer Ingelheim Profile
5.1.2 Boehringer Ingelheim Main Business
5.1.3 Boehringer Ingelheim Venous thromboembolism (VTE) Therapeutics Products, Services and Solutions
5.1.4 Boehringer Ingelheim Venous thromboembolism (VTE) Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 Boehringer Ingelheim Recent Developments
5.2 Bayer
5.2.1 Bayer Profile
5.2.2 Bayer Main Business
5.2.3 Bayer Venous thromboembolism (VTE) Therapeutics Products, Services and Solutions
5.2.4 Bayer Venous thromboembolism (VTE) Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 Bayer Recent Developments
5.3 Janssen
5.3.1 Janssen Profile
5.3.2 Janssen Main Business
5.3.3 Janssen Venous thromboembolism (VTE) Therapeutics Products, Services and Solutions
5.3.4 Janssen Venous thromboembolism (VTE) Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 Bristol-Myers Squibb Recent Developments
5.4 Bristol-Myers Squibb
5.4.1 Bristol-Myers Squibb Profile
5.4.2 Bristol-Myers Squibb Main Business
5.4.3 Bristol-Myers Squibb Venous thromboembolism (VTE) Therapeutics Products, Services and Solutions
5.4.4 Bristol-Myers Squibb Venous thromboembolism (VTE) Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 Bristol-Myers Squibb Recent Developments
5.5 Pfizer
5.5.1 Pfizer Profile
5.5.2 Pfizer Main Business
5.5.3 Pfizer Venous thromboembolism (VTE) Therapeutics Products, Services and Solutions
5.5.4 Pfizer Venous thromboembolism (VTE) Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 Pfizer Recent Developments
5.6 Daiichi-Sankyo
5.6.1 Daiichi-Sankyo Profile
5.6.2 Daiichi-Sankyo Main Business
5.6.3 Daiichi-Sankyo Venous thromboembolism (VTE) Therapeutics Products, Services and Solutions
5.6.4 Daiichi-Sankyo Venous thromboembolism (VTE) Therapeutics Revenue (US$ Million) & (2018-2023)
5.6.5 Daiichi-Sankyo Recent Developments
5.7 Portola Pharmaceuticals
5.7.1 Portola Pharmaceuticals Profile
5.7.2 Portola Pharmaceuticals Main Business
5.7.3 Portola Pharmaceuticals Venous thromboembolism (VTE) Therapeutics Products, Services and Solutions
5.7.4 Portola Pharmaceuticals Venous thromboembolism (VTE) Therapeutics Revenue (US$ Million) & (2018-2023)
5.7.5 Portola Pharmaceuticals Recent Developments
5.8 Armetheon
5.8.1 Armetheon Profile
5.8.2 Armetheon Main Business
5.8.3 Armetheon Venous thromboembolism (VTE) Therapeutics Products, Services and Solutions
5.8.4 Armetheon Venous thromboembolism (VTE) Therapeutics Revenue (US$ Million) & (2018-2023)
5.8.5 Armetheon Recent Developments
6 North America
6.1 North America Venous thromboembolism (VTE) Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Venous thromboembolism (VTE) Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Venous thromboembolism (VTE) Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Venous thromboembolism (VTE) Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Venous thromboembolism (VTE) Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Venous thromboembolism (VTE) Therapeutics Market Dynamics
11.1 Venous thromboembolism (VTE) Therapeutics Industry Trends
11.2 Venous thromboembolism (VTE) Therapeutics Market Drivers
11.3 Venous thromboembolism (VTE) Therapeutics Market Challenges
11.4 Venous thromboembolism (VTE) Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
